Cargando…
Elimination of infectious HIV DNA by CRISPR–Cas9
Current antiretroviral drugs can efficiently block HIV replication and prevent transmission, but do not target the HIV provirus residing in cells that constitute the viral reservoir. Because drug therapy interruption will cause viral rebound from this reservoir, HIV-infected individuals face lifelon...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050564/ https://www.ncbi.nlm.nih.gov/pubmed/31450074 http://dx.doi.org/10.1016/j.coviro.2019.07.001 |
_version_ | 1783502631621099520 |
---|---|
author | Das, Atze T Binda, Caroline S Berkhout, Ben |
author_facet | Das, Atze T Binda, Caroline S Berkhout, Ben |
author_sort | Das, Atze T |
collection | PubMed |
description | Current antiretroviral drugs can efficiently block HIV replication and prevent transmission, but do not target the HIV provirus residing in cells that constitute the viral reservoir. Because drug therapy interruption will cause viral rebound from this reservoir, HIV-infected individuals face lifelong treatment. Therefore, novel therapeutic strategies are being investigated that aim to permanently inactivate the proviral DNA, which may lead to a cure. Multiple studies showed that CRISPR–Cas9 genome editing can be used to attack HIV DNA. Here, we will focus on not only how this endonuclease attack can trigger HIV provirus inactivation, but also how virus escape occurs and this can be prevented. |
format | Online Article Text |
id | pubmed-7050564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-70505642020-03-02 Elimination of infectious HIV DNA by CRISPR–Cas9 Das, Atze T Binda, Caroline S Berkhout, Ben Curr Opin Virol Article Current antiretroviral drugs can efficiently block HIV replication and prevent transmission, but do not target the HIV provirus residing in cells that constitute the viral reservoir. Because drug therapy interruption will cause viral rebound from this reservoir, HIV-infected individuals face lifelong treatment. Therefore, novel therapeutic strategies are being investigated that aim to permanently inactivate the proviral DNA, which may lead to a cure. Multiple studies showed that CRISPR–Cas9 genome editing can be used to attack HIV DNA. Here, we will focus on not only how this endonuclease attack can trigger HIV provirus inactivation, but also how virus escape occurs and this can be prevented. 2019-08-23 2019-10 /pmc/articles/PMC7050564/ /pubmed/31450074 http://dx.doi.org/10.1016/j.coviro.2019.07.001 Text en This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Das, Atze T Binda, Caroline S Berkhout, Ben Elimination of infectious HIV DNA by CRISPR–Cas9 |
title | Elimination of infectious HIV DNA by CRISPR–Cas9 |
title_full | Elimination of infectious HIV DNA by CRISPR–Cas9 |
title_fullStr | Elimination of infectious HIV DNA by CRISPR–Cas9 |
title_full_unstemmed | Elimination of infectious HIV DNA by CRISPR–Cas9 |
title_short | Elimination of infectious HIV DNA by CRISPR–Cas9 |
title_sort | elimination of infectious hiv dna by crispr–cas9 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050564/ https://www.ncbi.nlm.nih.gov/pubmed/31450074 http://dx.doi.org/10.1016/j.coviro.2019.07.001 |
work_keys_str_mv | AT dasatzet eliminationofinfectioushivdnabycrisprcas9 AT bindacarolines eliminationofinfectioushivdnabycrisprcas9 AT berkhoutben eliminationofinfectioushivdnabycrisprcas9 |